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Abstract
Background: Pasteurella pneumotropica is a ubiquitous bacterium that is frequently isolated from laboratory
rodents and causes various clinical symptoms in immunodeficient animals. Currently two RTX toxins, PnxIA and
PnxIIA, which are similar to hemolysin-like high-molecular-weight exoproteins are known in this species. In this
study, we identified and analyzed a further RTX toxin named PnxIIIA and the corresponding type I secretion
system.
Results: The RTX exoprotein, PnxIIIA, contains only a few copies of the RTX repeat-like sequence and 3 large
repeat sequences that are partially similar to the outer membrane protein found in several prokaryotes.
Recombinant PnxIIIA protein (rPnxIIIA) was cytotoxic toward J774A.1 mouse macrophage cells, whereas cytotoxicity
was attenuated by the addition of anti-CD11a monoclonal antibody. rPnxIIIA could bind to extracellular matrices
(ECMs) and cause hemagglutination of sheep erythrocytes. Binding was dependent on the 3 large repeat
sequences in PnxIIIA. Protein interaction analyses indicated that PnxIIIA is mainly localized in the outer membrane
of P. pneumotropica ATCC 35149 in a self-assembled oligomeric form. PnxIIIA is less cytotoxic to J774A.1 cells than
PnxIA and PnxIIA.
Conclusions: The results implicate that PnxIIIA is located on the cell surface and participates in adhesion to ECMs
and enhanced hemagglutination in the rodent pathogen P. pneumotropica.
Background
Pasteurella pneumotropica is a Gram-negative rod-shaped
bacterium that is frequently isolated from the upper
respiratory tract of laboratory rodents. This bacterium is
a major causative agent of opportunistic infection in
rodents, and almost all infected immunocompetent
rodents exhibit unapparent infection. An earlier study
reported that coinfection by P. pneumotropica and Myco-
plasma pulmonis causes pneumonia in specific pathogen-
free mice [1]. A recent study reported that P. pneumotro-
pica infection disturbs the inflammation responses in
immunocompetent mice [2]. In immunodeficient rodents,
however, P. pneumotropica infection leads to various
serious diseases such as lethal pneumonia and sepsis. It is
well known that coinfection with Pneumocystis carinii and
P. pneumotropica leads to fatal pneumonia in B cell-defi-
cient mice [3,4]. In mice lacking functional MHC II, Tlr4,
and Nramp1 genes, experimental challenge with P. pneu-
motropica results in pulmonary infections [5,6]. Further-
more, orbital abscesses were caused by P. pneumotropica
infection in Cd28-mutated mice [7]. In laboratory rodents,
these infections could be effectively treated with antibiotics
[8-10], and hysterotomy and embryo transfer are known to
be the most effective treatments for eliminating P. pneu-
motropica completely [8]. However, both treatments are
time-consuming and require special facilities and equip-
ment. Therefore, to prevent P. pneumotropica infection in
laboratory rodents, it is necessary to periodically perform
microbiological monitoring of laboratory rodents and
maintain a clean environment in the rodent colony. To
perform microbiological monitoring and prevent infection, * Correspondence: h-sasaki@tokyo-med.ac.jp
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genicity of P. pneumotropica.
The phenotypic characteristics related to the virulence
of P. pneumotropica are hemagglutination and hemolysis
[11-13]. Two recently named exoproteins, PnxIA and
PnxIIA, both of which have C-terminal primary struc-
tures similar to the repeat in structural toxin (RTX) tox-
ins, have been identified and characterized as
hemolysin-like proteins in P. pneumotropica [13]. RTX
toxins have many copies of glycine-rich sequences, and
these toxins have been identified in many species of
Gram-negative bacterium, including Pasteurellaceae,
Enterobacteriaceae,a n dVibrionaceae [14-17]. Many
RTX toxins are reportedly capable of lysing erythrocytes;
thus, RTX toxins function as hemolysins [14,17]. In
addition, several RTX toxins act as leukotoxins and dis-
rupt actin cytoskeletons. LtxA produced by the period-
ontopathogen Aggregatibacter actinomycetemcomitans
specifically acts on human polymorphonuclear leuko-
cytes and macrophages while concurrently lysing ery-
throcytes to acquire iron [18-21]. Apx toxins (ApxIA
and ApxIIA) and lipopolysaccharides (LPSs) are the
major virulence factors for the porcine pathogen Actino-
bacillus pleuropneumoniae, and the Apx-LPS complex
promotes cytotoxicity toward porcine alveolar macro-
phages [22]. Furthermore, the Vibrio cholerae multifunc-
tional autoprocessing RTX toxin, which acts on cellular
actin protomers by cross-linking, disrupts the actin
cytoskeleton of cells [23-26]. As reported in recent stu-
dies, RTX toxins act on a variety of cells and cellular
matrices and are considered to have various effects on
host cells. Therefore, elucidating the functions of RTX
toxins may lead to a better understanding of the
mechanisms by which infectious agents cause infection.
In a previous study, we identified additional members
of the RTX toxin family, namely, PnxIA and PnxIIA, in
P. pneumotropica [13]. Details about their functions and
cytotoxicity, excluding their effects on sheep and mouse
erythrocytes, remain to be clarified, and it is important
to examine these proteins to prove that there are addi-
tional genes that code for proteins that are similar to
RTX toxins; this is important for elucidating P. pneumo-
tropica pathogenicity. In this study, we identified a third
gene encoding an RTX protein and characterized it in
terms of its in vitro cytotoxicity and hemolytic activity.
To understand the function of this RTX protein, we
attempted to determine its virulence characteristics
based on its predicted primary structure.
Results
Identification of the third gene encoding an RTX protein
A previous study revealed that P. pneumotropica carries
2 genes encoding hemolysin-like proteins that are simi-
lar to the RTX toxins PnxIA and PnxIIA [13]. Although
both structural protein-coding genes could be detected
using Southern hybridization or PCR, several unspecific
genes were also detected when the gene coding for
PnxIIA was targeted for detection by using PCR techni-
ques in reference strains and wild-type strains of
P. pneumotropica (data not shown). In this study, this
heterogenic PCR product was cloned, and the inserts of
the resultant plasmid pTAC-PX3 were sequenced. The
sequence of the inserts was similar to that of the
glycine-rich regions in pnxIIA; however, the detailed
sequence indicated the existence of an additional gene
that encodes a protein similar to the RTX toxin. Subse-
quently, we sequenced the uninserted regions from the
genomic DNA of P. pneumotropica ATCC 35149 by
using a previously constructed clone library [13] and
inverse PCR. Approximately 14 kb of related genes,
including 5 putative open reading frames (ORFs), were
finally identified (Figure 1A). To predict the functions of
the gene products, the deduced amino acid sequence of
each gene was analyzed on the basis of hidden Markov
model (HMM) profiles with a protein BLAST search
[27] or the Pfam database [28]. The pnxIII operon
comprised the genes encoding 3 functional component
proteins, namely, the OmpA-like protein, RTX exopro-
tein, and type I secretion system component proteins
(Figure 1A). The deduced amino acid sequences of tolC,
pnxIIIB, and pnxIIID were similar to that of the putative
outer membrane (OM) efflux protein of Neisseria sicca
ATCC 29256 (GenBank accession no. ZP_05317789)
with 68% similarity and 91% coverage, the LapA secre-
tion ATP-binding protein of Neisseria mucosa ATCC
25996 (ZP_05976520) with 86% similarity and 99% cov-
erage, and a membrane fusion protein of Simonsiella
muelleri ATCC 29453 (ZP_06753782) with 87% similar-
ity and 100% coverage, respectively. The proteins from
the 3 ORFs were indicated to form a type I secretion
system that transports the RTX protein across the
bacterial inner membrane (IM) and OM and finally
exports it into extracellular space.
The pnxIIIE gene product contains the OmpA domain
(Pfam reference: accession no. PF00691) in the C-terminus
and is 54% similar to the OM protein A of Cardiobacter-
ium hominis ATCC 15826 (ZP_05705729), with 84%
coverage.
Although the protein BLAST search yielded no highly
similar proteins, the deduced amino acid sequence of
pnxIIIA was partially similar (46%) to the RTX family
exoprotein of uropathogenic E. coli (UPEC) CFT073
[29] (NP_752300), i.e., 59% coverage. PnxIIIA is believed
to be an essential cytotoxic protein of the structural
RTX toxin.
Figure 1B shows the putative domains and repeat
sequence in the primary structure of PnxIIIA. PnxIIIA
did not have any significant identical conserved domains
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that were not significantly similar to conserved domains
were identified in the HMM dat a b a s e .I nb r i e f ,s e v e r a l
groups of bacterial immunoglobulin (Ig)-like domains
(Pfam reference: accession no. PF05345, PF02369,
PF02368, PF07532, and PF10648) and a hemagglutinin
repeat (PF05594) were scattered in the primary
sequence of PnxIIIA, and a hemolysin-type calcium-
binding repeat (PF00353) identical to nonapeptides of
the RTX repeat sequence in the C-terminal half was
present (Figure 1B). In particular, only 1 copy of amino
acid residues in position 2319-2327 (LDGGDGNDT)
was found to be identical to the RTX sequence; other-
wise, 2 RTX-like sequences were found in positions
2114-2122 (NFGGMGVSN; alternate amino acid resi-
dues are italicized) and 2377-2384 (IKGGT-NDT; the
missing amino acid residue is indicated with a hyphen).
PnxIIIA was also found to have a unique feature: 3
regions with large repeat sequences existed, and the
amino acid sequences in these regions were similar to
the repeat sequences of the extracellular protein toxin
identified in various prokaryotes, including important
pathogens (see multiple alignments in Additional file 1).
Of these, except for the unknown function of the RTX
exoprotein and hemolysin-type calcium-binding protein,
almost similar proteins were predicted to be localized in
the OM fraction and to function as adhesive proteins.
Cytotoxicity of rPnxIIIA
To assess the virulence characteristics of PnxIIIA, we
determined its cytotoxicity toward J774A.1 mouse
macrophage cells by using soluble rPnxIIIA. With
increasing rPnxIIIA concentrations, the cytotoxicity as
determined from the amount of lactose dehydrogenase
(LDH) released by the cells was increased during a 24-h
incubation (Additional file 2). In addition, we examined
and compared the cytotoxicity of 3 recombinant RTX
proteins identified in P. pneumotropica toward J774A.1
cells. During a 4-h incubation, native rPnxIA, rPnxIIA,
and rPnxIIIA exhibited 55.2% ± 7.2%, 45.2% ± 3.1% and
29.8% ± 7.1% cytotoxic to J774A.1 cells, respectively.
Compared with previously found RTX proteins, rPnxIIIA
was significantly less cytotoxic than rPnxIA and rPnxIIA
(P < 0.05). Several RTX toxins have been recognized in a
species-specific manner, and are found to be cytotoxic to
leukocyte function-associated antigen-1 (LFA-1)-bearing
Figure 1 Genetic organization and the predicted primary structure of PnxIIIA in P. pneumotropica ATCC 35149.( A )S c h e m a t i c
representation of the pnxIII operon genetic map and the functions of each gene. Circles represent potential transcriptional termination loops.
Predicted functions determined by the protein database are indicated below the gray boxes. (B) Schematic representation of probable domains
that were identified by comparing with the HMM database. The numbers represent the regions containing a large repeat sequence. Arrowheads
below the number box represent the position of sequence alignment in Additional file 1.
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toward J774A.1 mouse macrophage cells, it is important
to assess the effect of the presence of the LFA-1 receptor
in macrophage cells. Furthermore, we employed com-
parative analysis of PnxIIIA cytotoxicity by using parent
J774A.1 cells and anti-CD11a monoclonal antibody
(MAb)-treated J774A.1 cells as a neutralizing antibody.
Figure 2 shows the changes in cytotoxicity of both
J774A.1 cells and anti-CD11a MAb-treated cells cultured
with 1.0 μg/ml rPnxIIIA. During a 24-h incubation,
approximately 20-50% of cytolysis was inhibited by the
addition of anti-CD11a MAb. These results indicate that
the presence of the LFA-1 receptor may be required for
rPnxIIIA cytotoxicity toward J774A.1 cells.
ECM-binding ability and hemagglutination
Figures 3A to 3D show the changes in absorbance at
6 2 0n m( A 6 2 0 )w h e nr P n x I I I Aw a sg r a d u a l l ya d d e dt o
the ECM-coated 96-well plate; the changes in absor-
b a n c ew e r ed e t e r m i n e db ya ne n z y m e - l i n k e di m m u n o -
sorbent assay (ELISA). rPnxIIIA adhered to all tested
rodent ECMs, with adhesion increasing as the rPnxIIIA
concentration increased. In particular, the A620 of col-
l a g e nt y p eI( F i g u r e3 A )w a sh i g h e s ta m o n gt h et e s t e d
r o d e n tE C M s ,f o l l o w e db yt h a to fc o l l a g e nt y p eI I
(Figure 3B), which was the second most adhesive ECM
at a concentration of 50 μg/ml. Although the A620
values of collagen type IV and laminin were lower than
those of collagen type I and type II, rPnxIIIA was
confirmed to bind to both ECMs at higher concentra-
tions (Figure 3C and 3D). These results indicate that
rPnxIIIA can bind to rodent ECMs.
When compared with the domains in the HMM data-
base, several PnxIIIA domains have large repeat
sequences that contain the hemagglutinin repeat in the
primary sequence. rPnxIIIA was subjected to a hemag-
glutination assay with washed sheep erythrocytes. Figure
3E shows the results of the hemagglutination assay with
rPnxIIIA. Hemagglutination of sheep erythrocytes was
observed at rPnxIIIA concentrations exceeding 12.5 μg/
ml, indicating that rPnxIIIA participates in the hemag-
glutination of sheep erythrocytes.
We also measured the hemoglobin released from the
sheep erythrocytes when they were cultured with
rPnxIIIA; however, rPnxIIIA did not exhibit typical
hemolytic activity, indicating that rPnxIIIA is less
involved in hemolysis.
Characterization of deletion mutants of rPnxIIIA variants
To clarify the role of large repeat sequences in the func-
tions of PnxIIIA, we generated soluble rPnxIIIA and
deletion mutants of rPnxIIIA variants. rPnxIIIA,
rPnxIIIA209, rPnxIIIA197, and rPnxIIIA151 essentially
contained 255 kDa, 209 kDa, 197 kDa, and 151 kDa of
the parent PnxIIIA, respectively (Additional file 3A).
To compare the binding ability of the rPnxIIIA variants,
we performed binding assays with collagen type I coated
on the 96-well plate when 10 μg/ml of the rPnxIIIA var-
iants were applied. The A620 of wild-type rPnxIIIA was
0.55 ± 0.05, compared to 0.30 ± 0.06, 0.27 ± 0.01, and 0.26
± 0.04 for that of rPnxIIIA209, rPnxIIIA197,a n d
rPnxIIIA151, respectively (Additional file 3B). Almost all
A620s of the deletion mutant proteins were lower than
that of the parent rPnxIIIA. These results indicate that
rPnxIIIA can bind to ECMs and that its lack of repeat
sequences reduces its ability to bind ECMs.
We subjected the rPnxIIIA variants to a hemaggluti-
nation assay with washed sheep erythrocytes. Although
the deletion mutant protein rPnxIII209 promoted
hemagglutination at the same concentration as that of
rPnxIIIA, more than 25 μg/ml of both rPnxIIIA197 and
rPnxIIIA151 were required for hemagglutination (Addi-
tional file 3C). Although exact differentiation among the
rPnxIIIA variants was not observed in hemagglutination,
these results indicate that rPnxIIIA plays a role in
hemagglutination and that the repeat sequences located
in the C-terminal portion are necessary for enhanced
hemagglutination.
Localization and interaction of PnxIIIA
Figure 4A shows the results of the Western blotting
analysis of fractionated P. pneumotropica ATCC 35149
cells with anti-rPnxIIIA rabbit IgG. Signals of proteins
Figure 2 Changes in the cytotoxicity of the rPnxIIIA toward
J774A.1 mouse macrophage cells. The cytotoxicity was
determined by the release of LDH from J774A.1 cells with or
without treatment with anti-CD11a monoclonal antibody cultured
with rPnxIIIA.
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fractions; however, in the case of the OM fraction, the
intensity of the signal was strong and located above the
250-kDa marker and other fractions. This result was
also observed when the boiling time was increased to
20 min before sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and a redox reagent or
denaturant such as dithiothreitol or urea was added to
the OM fraction, as the position of the signal remained
unchanged. Therefore, PnxIIIA appeared to tightly bind
to proteins in the OM fraction. One candidate that
interacts with PnxIIIA in the OM fraction is the gene
product of pnxIIIE. Figure 4B shows the results of
the Western blotting analysis of fractionated cells with
Figure 3 The binding ability and hemagglutination activity of the rPnxIIIA. The binding ability of rPnxIIIA to the ECMs as determined by
ELISA (A to D) and hemagglutination activity of the rPnxIIIA with sheep erythrocytes (E). Changes in the ability of different concentrations of
rPnxIIIA to bind to the rat collagen type I (A), rat collagen type II (B), mouse collagen type IV (C), and mouse laminin (D), as determined by
measuring the A620. Changes in the hemagglutination activity of different concentration of rPnxIIIA with sheep erythrocytes (E).
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fractions, and the estimated protein size was assumed to
be the expected size of 30 kDa. These results may indi-
cate that PnxIIIE exists mainly in the IM and OM frac-
tion as a monomeric protein. Subsequently, we
examined the in vitro interaction between rPnxIIIA and
rPnxIIIE by using a soluble protein cross-linker, BS
3.
The reaction mixture was then pulled down via immu-
noprecipitation (IP) by using anti-rPnxIIIA IgG. Figure
4C shows the results of the Western blotting analysis of
cross-linking and the IP products detected with anti-
rPnxIIIA IgG. The signal was detected at 250-kDa when
only rPnxIIIA or rPnxIIIA and rPnxIIIE was used alone
without cross-linking (Figure 4C, lane 1 and 3). How-
ever, the positions of their signals appeared higher than
that of rPnxIIIA together with the parent 250-kDa
rPnxIIIA when only rPnxIIIA or rPnxIIIA and rPnxIIIE
was used after treatment with 50 mM BS
3 (Figure 4C,
lane 3 and 4). Furthermore, a shift of the signals was
observed with increasing reaction time when only
rPnxIIIA was used after treatment with BS
3 (Figure 4D).
These results indicate that rPnxIIIA interacts itself, and
self-assembled oligomerized PnxIIIA is located in the
OM fraction in P. pneumotropica ATCC 35149.
Figure 5 shows immunoelectron microscopy images of
P. pneumotropica ATCC 35149 cells. Anti-rPnxIIIA IgG
bound mainly to the cell surface, and few cellular and
extracellular substances were gold-labeled, indicating
that PnxIIIA is habitually localized on cell surfaces.
Ability of adherence, hemagglutination, and cytotoxicity
in reference strains
Initially, we performed Southern blotting analysis for
detecting partial sequences of pnxIIIA.O n l yg e n o m i c
DNA from P. pneumotropica CCUG 26450 was con-
firmed to include the partial gene containing the RTX
repeat (Additional file 4); however, numerous signals
including putative unspecific signals appeared using the
Figure 4 Localization of PnxIIIA and the protein interaction analysis of rPnxIIIA. (A) Western blotting analysis of the cell fraction prepared
from P. pneumotropica ATCC 35149 cells and culture by using anti-rPnxIIIA IgG. Lanes: 1, SC fraction; 2, IM fraction; 3, OM fraction; 4, UC fraction.
(B) Western blotting analysis of the cell fraction prepared from P. pneumotropica ATCC 35149 cells and culture by using anti-rPnxIIIE IgG. Lanes: 1,
SC fraction; 2, IM fraction; 3, OM fraction; 4, UC fraction. (C) Western blotting analysis of rPnxIIIA by using anti-rPnxIIIA IgG after cross-linking with
only rPnxIIIA or the rPnxIIIE protein and IP with anti-rPnxIIIA IgG. Lanes: 1, rPnxIIIA without cross-linking; 2, 20 μg of rPnxIIIA alone cross-linked
with 50 mM BS
3 for 60 min and immunoprecipitated; 3, mixture of both rPnxIIIA and rPnxIIIE proteins without cross-linking; 4, 20 μg of both
rPnxIIIA and rPnxIIIE proteins cross-linked with 50 mM BS
3 for 60 min and immunoprecipitated. (D) Western blotting analysis of rPnxIIIA by using
anti-rPnxIIIA IgG after different treatment times with rPnxIIIA alone cross-linked with 50 mM BS
3 and immunoprecipitated with anti-rPnxIIIA IgG.
Lanes: 1, rPnxIIIA without cross-linking; 2, rPnxIIIA with cross-linking for 5 min; 3, rPnxIIIA with cross-linking for 10 min; 4, rPnxIIIA with cross-
linking for 30 min; 5, rPnxIIIA with cross-linking for 60 min. Arrows indicate the position of the bands that appeared.
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of PnxIIIA. These results indicate that the gene encod-
ing PnxIIIA is heterogenic and diversified. Subsequently,
we performed Western blotting analysis of total protein
obtained from cultured cells with anti-rPnxIIIA.
Although PnxIIIA was detected in the 5 reference
strains of P. pneumotropica by Western blotting, the
estimated size and intensity of the detected signals were
varied among the strains (Figure 6A). In brief, the mole-
cular weight of the detected signals obtained from
ATCC 12555 and CCUG 36632 was approximately
250 kDa, whereas those obtained from CCUG 262450
and CCUG 26451 were less than 250 kDa. Furthermore,
the signals from both ATCC 35149 and CCUG 26450
had higher intensity than those of the other reference
strains. The A490 values determined by whole-cell bind-
ing assays with the collagen type I of the PnxIIIA-
producing strains were significantly higher than that of
CCUG 26453, which was not confirmed to produce
PnxIIIA (P < 0.05; Figure 6B). Hemagglutination activity
was clearly observed in the 5 reference strains, whereas
CCUG 26453 exhibits insignificant activity (Figure 6C).
Although the existence of PnxIIIA was confirmed to
participate in the activity of adherence and hemaggluti-
nation, these activities may be varied among the strains.
Furthermore, the cytotoxicity of reference strains toward
J774A.1 cells was examined (Figure 6D). Strains ATCC
35149, ATCC 12555, and CCUG 36632 exhibited more
than 70% cytotoxicity; the other strains exhibited less
than 50% cytotoxicity. Although the cytotoxicity of each
strain did not absolutely coincide with those of the
strains that produce PnxIIIA, strain CCUG 26453,
which was not confirmed to produce PnxIIIA, was
demonstrated to be less cytotoxic toward J774A.1 cells.
These results also indicate that rodent isolates were
found to have binding and hemagglutination activities;
on the other hand, P. pneumotropica CCUG 26453,
which was recorded to be isolated from birds, was not
confirmed to have these activities (Table 1).
Discussion
In this study, we identified and characterized a third
gene that encodes an RTX exoprotein in P. pneumotro-
pica. A known protein that is similar to PnxIIIA is the
RTX exoprotein, which was identified in a UPEC strain
[29]. Lloyd et al. [33] reported that a mutant strain in
which the gene encoding this RTX exoprotein was
deleted colonized bladders and kidneys less efficiently
than the wild-type UPEC strain. These results indicate
that this RTX toxin may participate in bacterial coloni-
zation. To characterize the virulence properties of
PnxIIIA, we focused on its adhesion and hemagglutina-
tion activities as well as its cytotoxicity. For instance,
100-500 ng/ml recombinant CyaA from Bordetella per-
tussis lysed approximately 100% of murine monocytes
over a 4-h period [34]. Although the conditions were
different, PnxIIIA was assumed to be weakly cytotoxic
compared to the RTX toxin, which is highly toxic.
Several RTX toxins that act as leukotoxins reportedly
bind to b2-integrin LFA-1 (CD11a/CD18) on species-
specific leukocytes [30-32,35]. LFA-1 is expressed on the
cell surface as a glycoprotein composed of the a subunit
of CD11 and the b subunit of CD18. In the case of
LktA produced by Mannheimia haemolytica,w h i c hi s
the principal pathogen of bovine respiratory diseases
complex, can bind to the bovine CD11a of LFA-1 [31].
LtxA produced by A. actinomycetemcomitans recognizes
the b-propeller domain of human CD11a [36]. The cyto-
toxicity of rPnxIIIA toward J774A.1 cells was success-
fully attenuated by the addition of anti-CD11a MAb,
which can react to mouse CD11a as a neutralizing anti-
body, suggesting that the a subunit of mouse LFA-1
may be required for its cytotoxicity toward J774A.1
cells. The detailed mechanisms underlying CD11a
mediated PnxIIIA cytolysis need to be clarified in future
studies.
One of the features of this high-molecular-weight pro-
tein is that it has 2-3 different copies of 3 large repeat
sequences. These copies, although not completely iden-
tical, are highly similar and contain several bacterial
Ig-like domains and a hemagglutination repeat. The
deletion mutant proteins were observed to bind less to
rodent ECMs compared with the parent rPnxIIIA. All 3
Figure 5 Transmission electron micrographs of P. pneumotropica
ATCC 35149 cells by immunoelectron microscopy with anti-
rPnxIIIA IgG. Transmission electron micrographs of the P.
pneumotropica ATCC 35149 cells that were first reacted with anti-
rPnxIIIA IgG and then labeled with gold particles (10-nm) conjugated
with rabbit IgG antibody. Arrows indicate the areas where gold
labeling appeared on the cell surface. Left panel, cross-section of the
bacterial cell. Right panel, longitudinal section of the bacterial cell.
Bar = 0.2 μm.
Sasaki et al. BMC Microbiology 2011, 11:55
http://www.biomedcentral.com/1471-2180/11/55
Page 7 of 14large repeat sequences contained regions that were par-
tially similar to several groups of bacterial Ig-like
domains, including groups 1, 2, and 4. Many Ig-like
domains that belong to these groups are indicated to
form an Ig-like fold and are reportedly present in bac-
terial cell-surface proteins such as intimins and invasins
[37-40]. The other groups of Ig-like domains have also
been suggested to form Ig-like folds and play in a role
in adhesion to host cells, contributing to pathogenicity
[41]. In accordance with our experimental results, these
sequences are indispensable for adherence to ECMs, and
thus, the 3 large repeat sequences in PnxIIIA may be
required for the pathogenicity of P. pneumotropica.
All RTX proteins in P. pneumotropica have only 3-7
RTX repeats and RTX-like sequences, and the numbers of
the repeat sequence are fewer than those in the other
highly toxic members of RTX toxin family [15,17]. For
example, the toxicity of the B. pertussis RTX toxin CyaA is
Figure 6 Presence of PnxIIIA, binding ability, hemagglutination activity, and cytotoxicity of reference strains of P. pneumotropica. (A)
Western blotting analysis of cell lysates (5 μg of total protein) of the reference strains by using anti-rPnxIIIA IgG. (B) The binding ability of the
reference strains against to the rat collagen type I. A 1-way ANOVA determined that there were significant differences between the strains (P <
0.05). The mean value of A490 of strain ATCC 35149 (numbered as 1) or CCUG 26453 (5) is significantly different from that of the other strains by
determination of Duncan’s multiple-range test (P < 0.05). (C) Changes in hemagglutination activity of the reference strains with sheep
erythrocytes. (D) Percentage of cytotoxicity determined by LDH release from the supernatant of J774A.1 cells cultured with reference strains of P.
pneumotropica. A 1-way ANOVA determined that there were significant differences between the strains (P < 0.05). The mean values of
cytotoxicity (%) of strain ATCC 35149 (numbered as 1) or ATCC 12555 (2) and CCUG 36632 (6) are significantly different from that of the other
strains by determination of Duncan’s multiple-range test (P < 0.05). All sections of numbers are represented as follows: 1, ATCC 35149; 2, ATCC
12555; 3, CCUG 26450; 4, CCUG 26451; 5, CCUG 26453; 6, CCUG 36632.
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protein acyltransferase CyaC, leading to the binding of
B. pertussis to eukaryotic cells [42,43]. In the 3 RTX toxins
in P. pneumotropica, none of the predicted acylation pro-
tein-coding genes were found in neighboring genes, and
the acylation site was also not found in the primary struc-
ture of the proteins, indicating that the RTX proteins iden-
tified in P. pneumotropica have a structure that is unique
to the RTX toxin family. Furthermore, the phenotypic and
genetic characteristics of wild-type strain of P. pneumotro-
pica were reportedly diversified with an increase in the
number of isolates [44]. PnxIIIA is also assumed to be
heterogenic and diversified among the P. pneumotropica
strains. It is necessary to further clarify the relation-
ships between the diversity and the role of PnxIIIA in
P. pneumotropica infection.
Conclusions
In this study, we identified and characterized a third
gene encoding the RTX exoprotein PnxIIIA. The results
indicated that rPnxIIIA has cytotoxicity toward J774A.1
cells. Our results also implicate that PnxIIIA is localized
on the cell surface and is related to adherence to the
host ECMs and hemagglutination.
Methods
Bacterial strains and plasmids
The P. pneumotropica reference and E. coli strains and
plasmids used in this study are listed in Table 1.
pnxIIIA was first amplified using the primer pair
pnx3A-pcr-f and pnx3A-pcr-r (Additional file 5 lists
the oligonucleotide primers), and subsequently, the
purified PCR product was used for a second amplifica-
tion of pnxIIIA by using the primer pair pnx3A-pro-
tein-f and pnx3A-protein-r. The amplicon was cloned
into an entry vector, pENTR/SD/D-TOPO vector
(Invitrogen, Carlsbad, CA, USA), and subsequently
recombined with the destination vector pBAD-
DEST49 (Invitrogen), yielding pBAD-Pnx3A. Mutant
PnxIIIA expression vectors, pBAD-Pnx3A209,p B A D -
Pnx3A197,a n dp B A D - P n x 3 A 151, were also constructed
as described below.
Table 1 Bacterial strains and plasmids used in this study




ATCC 35149 Type strain, biotype Jawetz, isolated from mouse lung ATCC
a [50]
ATCC 12555 Biotype Heyl, isolated from mouse ATCC [51]
CCUG 26450 Biotype Jawetz, isolated from gerbil CCUG
b
CCUG 26451 Biotype Jawetz, isolated from hamster CCUG
CCUG 26453 Biotype Heyl, isolated from bird CCUG
CCUG 36632 Biotype unknown, isolated from murine nose CCUG
Escherichia coli
DH5a Cloning strain Stratagene
TOP10 Cloning strain Invitrogen




pTAC-1 Cloning vector, Ap
r Biodynamics
Laboratory
pENTR/SD/D-TOPO Entry vector, Km
r Invitrogen




pET300/NT-DEST Protein expression vector, N-terminal fusions to six-Histidine tag, Ap
r Invitrogen
pTAC-PX3 0.5-kb pnxIIIA PCR fragment This study
pBAD-Pnx3A Entire pnxIIIA gene cloned into pBAD-DEST49 This study
pBAD-Pnx3A209 1.3-kb sequence of repeat 1 deleted from pBAD-Pnx3A This study
pBAD-Pnx3A197 1.7-kb sequence of repeats 2 and 3 deleted from pBAD-Pnx3A This study
pBAD-Pnx3A151 3.0-kb sequence of repeats 1, 2, and 3 deleted from pBAD-Pnx3A This study
pET-Pnx3E Entire pnxIIIE gene cloned into pET300/NT-DEST This study
aAmerican Type Culture Collection.
bCulture Collection of the University of Göteborg.
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All P. pneumotropica strains were maintained in a brain-
heart infusion medium (BD, Cockeysville, MD, USA) at
37°C and incubated for 48 h. Transformed E. coli
bacteria were grown at 37°C for 16 h in Luria-Bertani
medium supplemented with 100 μg/ml ampicillin,
50 μg/ml kanamycin, 125 μM 5-bromo-4-chloro-3-
indolyl-b-D-galactopyranoside, and 1 mM isopropyl-b-
D-thiogalactopyranoside, if required, to select and
maintain recombinant E. coli. To induce gene expression
in the recombinant E. coli, the cells were incubated at
37°C for 2-3 h until the optical density (OD, 600 nm)
reached 1.0. Subsequently, 0.1% L-arabinose was added
to the culture. During the induction of gene expression,
the cell culture was incubated at room temperature
(RT) for 16 h.
J774A.1 mouse macrophage cells (JCRB9108) were
provided by Health Science Research Resources Bank
(Osaka, Japan). The J774A.1 cells were cultivated at
37°C in 5% CO2 in Dulbecco’s modified Eagle medium
(DMEM; Wako, Osaka, Japan) supplemented with 10%
fetal bovine serum, 100 U penicillin, and 100 μg/ml
streptomycin sulfate.
Nucleic acid extraction and purification
Plasmid and genomic DNA were extracted according to
the method described in a previous study [45].
TA cloning, inverse PCR, and DNA sequencing
Af r a g m e n to fpnxIIIA was amplified with the primer
pair pnx2A-f and pnx2A-r by using Ex Taq (Takara
Bio, Shiga, Japan), and the amplified product was puri-
fied using SUPREC-PCR (Takara Bio). The purified
PCR amplicons were ligated with the pTAC-1 vector
(Biodynamics Laboratory, Tokyo, Japan), and E. coli
DH5a was transformed with the resultant vectors. The
clones were screened via blue-white selection and
direct colony PCR by using the M13 primer pair. For
i n v e r s eP C R ,t h eg e n o m i cD N Ao fP. pneumotropica
ATCC 35149 was digested with various restriction
enzymes that recognized a 6-nucleotide sequence, and
subsequently, the digestion product was self-ligated
with T4 ligase (Takara Bio) and then used as an
inverse PCR template. Inverse PCR was performed
using gradient PCR to determine the optimum anneal-
ing temperature for a model DNA Engine PTC-200
(Bio-Rad Laboratories, Hercules, CA, USA). The PCR
products were ligated with the pTAC-1 vector and
screened to ensure the accuracy of sequencing. Cycle
sequencing was performed using the BigDye termina-
tor premix (Applied Biosystems, Foster City, CA,
USA). The products of the sequencing reaction were
analyzed using an ABI 310 or ABI 3730XL DNA analy-
zer (Applied Biosystems).
Purification of recombinant Pnx proteins
rPnxIIIA was extracted and purified from the cell cul-
ture of E. coli strain TMU0812 harboring pBAD-Pnx3A.
The cultured cells were suspended in 20 mM Tris-HCl,
150 mM NaCl, 5 mM imidazole, and 1 mM 2-mercap-
toethanol (pH 8.0, binding buffer); they were then bro-
k e nb ys o n i c a t i o n .T h es o n i c a t ew a sc e n t r i f u g e da t
7,000 × g for 10 min and filtered using a 0.45-μmf i l t e r
unit (Millipore, Billerica, MA, USA). The supernatant
was loaded onto a 1-ml His-trap HP affinity column
(GE Healthcare, Amersham, UK) mounted on an
ÁKTAprime plus fast protein liquid chromatography
device (FPLC device; GE Healthcare), and chromatogra-
phy was performed by running a program for histidine-
tagged protein purification according to the manufac-
turer’s instructions. The collected sample was then
eluted as a fraction in a buffer containing 20 mM Tris-
HCl, 150 mM NaCl, 500 mM imidazole, and 1 mM 2-
mercaptoethanol (pH 8.0; elution buffer). Fractions that
mainly contained rPnxIIIA were monitored and con-
firmed by SDS-PAGE. For purification of rPnxIIIE,
E. coli BL21-AI cultures harboring pET-Pnx3E were
extracted in a binding buffer containing 6 M guanidine
hydrochloride, and the extracts were purified with an
elution buffer containing 6 M urea, similar to the
method used to purify rPnxIIIA. The solvent of
rPnxIIIA and rPnxIIIE was exchanged to a buffer con-
taining 20 mM Tris-HCl and 150 mM NaCl by using
FPLC and dialysis, respectively.
Purification of native rPnxIA and rPnxIIA was performed
briefly according to previous described methods [13].
Generation of deletion mutants of rPnxIIIA variants
To compare the function of the unique repeat sequences
in the rPnxIIIA variants, deletion mutant rPnxIIIA
expression vectors were constructed. In brief, deletion
mutant expression vectors pBAD-Pnx3A209,w h i c h
lacked amino acid residues of a repeat sequence at posi-
tion 287-735 (Figure 1B; Repeat 1), and pBAD-
Pnx3A197, which lacked amino acid residues of a repeat
sequence at position 1097-1666, (Figure 1B; Repeats 2
and 3) were directly constructed using the wild-type
protein expression vector pBAD-Pnx3A as the template
with primer pairs pnx3A-209-f and pnx3A-209-r and
pnx3A-197-f and pnx3A-197-r, respectively. A PrimeS-
TAR Mutagenesis Basal Kit (Takara Bio) was used to
create these deletion mutant expression vectors. Finally,
pBAD-Pnx3A151, which lacked both repeat sequences,
was constructed with the primer pair pnx3A-197-f and
pnx3A-197-r with pBAD-Pnx3A209 as the PCR template.
All the constructs were confirmed with DNA sequen-
cing. The expression and purification of rPnxIIIA var-
iants were performed in the same manner as that used
for the wild-type rPnxIIIA.
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The cytotoxicity of the recombinant Pnx proteins
toward J774A.1 cells was determined via a LDH release
assay that was performed according to the methods of
Basler et al. [34] with minor modifications. Prior to
incubation, the concentration of J774A.1 cells in a 96-
well plate was adjusted 1 × 10
5 cells per well. The cells
were grown in fresh DMEM supplemented with 20 mM
CaCl2 and appropriate antibiotics. rPnxIIIA was added
to the wells such that its concentrations were 0.1, 0.5,
and 1.0 μg/ml of the final concentrations. The plate was
incubated at 37°C in 5% CO2 for up to 24 h. LDH
release from the J774A.1 cells was measured at 1, 2, 4,
6, 12, and 24 h by using the supernatant from the trea-
ted cells; a cytotoxicity detection kit (Roche Diagnostics,
Mannheim, Germany) was used for this purpose. For
the comparison of cytotoxicity among rPnxIA, rPnxIIA,
and rPnxIIIA, 1.0 μg/ml of each recombinant protein
was incubated with the J774A.1 cells for 4 h. Thereafter,
LDH release from the J774A.1 cells was measured.
Furthermore, to assess the effect of existence of CD11a
on inhibition of rPnxIIIA-induced cytolysis, LDH release
from the J774A.1 cells with the addition of 1.0 μg/ml
rPnxIIIA with or without 1.0 μg/ml anti-CD11a rat
MAb (Abcam, Cambridge, UK), which cross-reacts with
the a subunit of mouse CD11 as a neutralizing anti-
body, was measured after 2, 6, 12, and 24 h of incuba-
tion as described above. To assess the cytotoxicity of
P. pneumotropica reference strains toward J774A.1 cells,
a whole bacterial cell cytotoxicity assay was performed
briefly according to the methods of Kehl-Fie et al. [46].
The results were reported as the percentage of LDH
released from all the lysed cells. The experiments were
repeated in triplicate.
ECM-binding assay
ELISA was used to determine the binding of rPnxIIIA
variants to components of rodent ECMs. In brief, a 96-
well microtiter plate coated with rat collagen type I (BD
BioCoat, BD) was used for the binding assay of rat col-
lagen type I, and rat collagen type II (Chondrex, Red-
mond, WA, USA), mouse collagen type IV (BD), and
mouse laminin (BD) were differently coated on a 96-
well microplate (As one, Osaka, Japan) according to the
manufacturer’s instructions. ELISA was performed with
a protein detector AP microwell kit (KPL, Gaithersburg,
MD, USA), anti-6× Histidine tag monoclonal antibody
(Biodynamics laboratory), and rPnxIIIA variants, the
concentrations of which were adjusted to 0.5-50 μg/ml
of the final concentration.
For the whole-cell binding assay of P. pneumotropica
reference strains, precultured cells were adjusted the OD
reached 1.0 and incubated on a 96-well microtiter plate
coated with rat collagen type I (BD) at 37°C for 24 h.
Thereafter, the plate was briefly washed and stained with
0.1% safranin, according to the method of Davey and
Duncan [47]. The quantification of adherent cells was
determined by measuring the A490 with a plate reader.
Hemagglutination and hemolytic assay
Defibrinated sheep blood was obtained from Nippon
Bio-Test Laboratories (Tok y o ,J a p a n )a n dw a s h e d3
times with sterilized phosphate-buffered saline (PBS)
prior to conducting the assays. Hemagglutination activ-
ity was determined in V-cut bottom 96-well microtiter
plates (Corning, Horseheads, NY, USA). Fifty micro
milliliters of diluted rPnxIIIA variants or overnight cul-
tures of P. pneumotropica reference strains were added
to wells containing 2% sheep erythrocytes. The plate
was incubated at RT for 1 h, and thereafter, the plate
was imaged and visualized with a GeneGenius Bio Ima-
ging System (Syngene, MD, USA). A hemolysis assay
was performed according to a previously described
method [13] that used 2% sheep erythrocytes.
Generation and purification of rabbit antisera
In brief, crude rabbit antisera against the entire rPnxIIIA
and rPnxIIIE proteins were prepared using the methods
of Schaller et al. [48]. The crude antisera were further
purified on an HiTrap rProtein A FF column (GE
Healthcare) mounted on an FPLC device, and rabbit
IgG was prepared for immunological experiments. The
Institutional Animal Care and Use Committee of Tokyo
Medical University approved all of the animal experi-
mental procedures described here.
Fractionation of bacterial cell culture
Fractionation of the OM fraction, IM fraction, and solu-
ble cell (SC) components was performed according to the
methods of Valle et al. [49]. P. pneumotropica ATCC
35149 cells in the mid-log phase were harvested, resus-
pended in 10 mM HEPES (pH 7.5) with 50 mM NaCl
and 0.1 mg/ml lysozyme, and disrupted by sonication.
The sonicate was centrifuged at 7,000 × g for 10 min, and
subsequently, the supernatant was centrifuged at 100,000
× g f o r1hb yu s i n gaB e c k m a nO p t i m aT LT a b l e t o p
Centrifuge (Beckman Coulter, Brea, CA, USA). The
supernatant was used as the SC fraction, and the pellet
containing the bacterial membrane was resuspended in a
buffer containing 0.5% sarkosyl (N-laurylsarcosine) and
allowed to stand for 30 min at RT. The sarkosyl-soluble
fraction was centrifuged at 100,000 × g for 1 h. The
supernatant was used as the IM fraction, and the pellet
was resuspended in a 500 μl of 10 mM HEPES (pH 7.5)
with 50 mM NaCl, 1% sarkosyl, and 10 mM EDTA and
used as the OM fraction. To prepare a cell-free superna-
tant, the P. pneumotropica ATCC 35149 culture in the
mid-log phase was centrifuged at 7,000 × g for 10 min,
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size filter (Millipore) followed by a 0.45-μm pore size fil-
ter (Millipore). The filtrate was ultrafiltrated at 1000 × g
for 20 min by using AmiconUltra-15 (Millipore). The
resultant solution was used as the ultrafiltrated culture
supernatant (UC) fraction. For SDS-PAGE analysis, the
concentration of the SC, IM, OM, and UC samples were
adjusted to 0.2 mg/ml, and 10 μl of each sample were
subjected to 10% SDS-PAGE.
Cross-linking and pull-down assay
To determine the in vitro interaction of rPnxIIIA and
rPnxIIIE, chemical cross-linking and IP were performed.
A cross-linker for soluble proteins, bis[sulfosuccinimidyl]
suberate-d0 (BS
3-d0; Thermo Fisher Scientific, Waltham,
MA, USA), was used for the cross-linking reaction of
rPnxIIIA and rPnxIIIE according to the manufacturer’s
instructions. To terminate the cross-linking reaction,
20 mM NH4HCO3 was added. Thereafter, a mixed solu-
tion was subjected to IP by using an IP kit, Dynabeads
Protein G (Invitrogen), and rabbit IgG against rPnxIIIA
according to the manufacturer’s instructions. The resul-
tant solution was subjected to SDS-PAGE, and the inter-
action of rPnxIIIA with rPnxIIIA or rPnxIIIE was
detected by Western blotting as described below.
Western blotting and Southern hybridization
Fractions of the P. pneumotropica cell culture, IP-treated
sample, and cell lysates of P. pneumotropica reference
strains were analyzed by Western blotting by using anti-
rPnxIIIA IgG (1:20,000) or anti-rPnxIIIE IgG (1:20,000),
followed by SDS-PAGE separation. Anti-rabbit IgG anti-
body conjugated to horseradish peroxidase (HRP;
Thermo Fisher Scientific) for anti-rPnxIIIA IgG was
used as secondary antibodies at a dilution of 1:50,000.
To detect hybridization signals, the Femto Western che-
miluminescence reagent (Thermo Fisher Scientific) was
used as a substrate for HRP.
For Southern hybridization, digoxigenin-11-dUTP-
labeled pnxIIIA probes were generated using the primer-
pair pnx3A-probe-f and pnx3A-probe-r and the genomic
DNA of P. pneumotropica ATCC 35149. The genomic
DNAs of the reference strains were digested with HindIII
and loaded on agarose gels. The hybridization and detec-
tion protocol used has been described previously [13].
Immunoelectron microscopy
Bacterial cells were fixed with 4% (w/v) paraformalde-
hyde, 0.25% (v/v) glutaraldehyde, and 5% sucrose in
1.5 ml of 0.1 M phosphate buffer (pH 7.4) for 2 h at
4°C. The cells were harvested at 1000 × g for 10 min.
The pellets were then rinsed with the same buffer and
dehydrated by passing them through an ethanol series.
Samples were embedded in LR-white resin. Thin
sections were placed in PBS with 5% bovine serum
albumin (BSA) for 30 min at RT and then incubated
with rabbit anti-PnxIIIA IgG diluted to 1:100 with 1%
BSA in PBS for 4 h at RT. The sections were washed 3
times in PBS and incubated with goat anti-rabbit IgG
conjugated with 10-nm immunogold particles (BBIn-
ternational, Cardiff, UK) diluted to 1:50 with 5% BSA
in PBS for 1 h. The sections were subsequently stained
with uranyl acetate and lead citrate and viewed under
a JEOL JEM-1200EX electron microscope (JEOL,
Tokyo, Japan) at 80 kV.
Nucleic acid accession numbers
The nucleotide sequences of pnxIIIE, pnxIIIA, pnxIIIB,
pnxIIID,a n dtolC were deposited in GenBank through
DNA Data Bank of Japan, and the assigned accession
numbers were AB568084, AB568085, AB568086,
AB568087, and AB568088, respectively.
Additional material
Additional file 1: Multiple alignments of the 3 regions with repeat
sequences in PnxIIIA. The numbers at the terminus represent the
position of each protein. Identical residues and similarity substitutions are
highlighted in black and gray, respectively. Each organism and protein
are represented by abbreviations as follows: PN, PnxIIIA from P.
pneumotropica ATCC 35149; PR, RTX family exoprotein A from Proteus
mirabilis ATCC 29906 (accession no., EEI46927); EC, putative RTX family
exoprotein from E. coli CFT073 (AAN78844); CA, cell wall surface anchor
family protein from Cardiobacterium hominis ATCC 15826 (EEV87836); AN,
possible LPXTG anchored adhesin from Anaerococcus tetradius ATCC
35098 (EEI83830); MH, hemolysin-type calcium-binding protein from
Marinomonas sp. strain MWYL1 (ABR70778); VC, RTX toxin from V.
cholerae M66-2 (ACP05873); PS, putative outer membrane adhesin-like
protein from Psychrobacter sp. PRwf-1 (ABQ94037); FL, probable
aggregation factor core protein MAFp3 from Dokdonia donghaensis
MED134 (EAQ39910); ST, putative RTX family exoprotein from
Streptococcus suis 98HAH33 (ABP91341).
Additional file 2: Changes in cytotoxicity toward J774A.1 cells
cultured with different concentrations of rPnxIIIA. The cytotoxicity
was determined by the release of LDH from J774A.1 mouse macrophage
cells.
Additional file 3: The binding ability and hemagglutination activity
of the rPnxIIIA variants. (A) Coomassie blue-stained SDS-PAGE analysis
of rPnxIIIA variants. Lanes: M, protein ladder; 1, wild-type rPnxIIIA; 2,
rPnxIIIA209; 3, rPnxIIIA197; 4, rPnxIIIA151. (B) Ability of rPnxIIIA variants (10
μg/ml) to bind to the rat collagen type I measured by A620. Numbers
are represented as follows: 1, wild-type rPnxIIIA; 2, rPnxIIIA209;3 ,
rPnxIIIA197; 4, rPnxIIIA151. (C) Changes in hemagglutination activity of
different concentration of the rPnxIIIA variants with sheep erythrocytes.
Numbers are represented as follows: 1, rPnxIIIA209; 2, rPnxIIIA197; and 3,
rPnxIIIA151.
Additional file 4: Southern blotting analysis of reference strains of
P. pneumotropica using pnxIIIA probes. The arrow indicates the
position of the expected bands.
Additional file 5: Oligonucleotide primers used in this study. Primer
name, sequence, target gene, and their purpose are listed.
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